SCHEMBL30154343

SCHEMBL30154343

CC(C)(C#CC(=O)O)NC(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
CTSS P25774 8/20 0.34
CTSK P43235 8/20 0.34
CA1 P00915 2/20 0.33
CA7 P43166 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
CA12 O43570 1/20 0.33
CA14 Q9ULX7 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CTSL P07711 2/20 0.33
CTSB P07858 2/20 0.33
BTK Q06187 1/20 0.33
CA2 P00918 1/20 0.33
DGAT1 O75907 1/20 0.32
AKT1 P31749 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14282687 0.82 CTSK (0.41) MEN1GAAKMT2ACTSSCTSK
SCHEMBL25874746 0.81 CTSK (0.32) MEN1GAAKMT2ACTSSCTSK
SCHEMBL29957057 0.76 CTSK (0.37) MEN1GAAKMT2ACTSSCTSK
SCHEMBL6292986 0.75 TDP1 (0.37) MEN1GAAKMT2ACTSSCTSK
SCHEMBL2187338 0.74 NPC1 (0.36) MEN1GAAKMT2ACTSSCTSK
SCHEMBL2911305 0.74 CTSS (0.40) MEN1KMT2ACTSSCTSKTDP1
SCHEMBL132657 0.69 DGAT1 (0.42) MEN1GAAKMT2ACTSKCA1
SCHEMBL21410149 0.69 PTPN11 (0.49) MEN1GAAKMT2ACTSSCTSK
SCHEMBL25229366 0.69 MEN1 (0.44) MEN1GAAKMT2ACTSSCTSK
SCHEMBL76832 0.69 KDM4C (0.41) MEN1GAAKMT2ACTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 EP disclosed
WO-2023004376-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-01-26 WO disclosed